Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Oliver

Showing results (181-190 of 230) with videos related to

Pageof 23
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 6, 2021
Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patientsMichael Metz, Dieter Semsek, Gunther Rogmans, et al.
Circulation Research|May 20, 2006
Formation of the venous pole of the heart from an Nkx2-5-negative precursor population requires Tbx18Vincent M Christoffels, Mathilda T M Mommersteeg, Mark-Oliver Trowe, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 5, 2021
Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort studyCarla Colombo, Gianfranco Alicandro, Mark Oliver, et al.
Clinical Genitourinary Cancer|August 2, 2024
Final Analysis of a Noninterventional Study on Cabozantinib in Patients With Advanced Renal Cell Carcinoma After Prior Checkpoint Inhibitor Therapy of the German Interdisciplinary Working Group on Renal Tumors (IAG-N)Grünwald Viktor, Bögemann Martin, Rafiyan Mohammad-Reza, et al.
Scientific Reports|July 2, 2025
AI-based CT assessment of 3117 vertebrae reveals significant sex-specific vertebral height differencesViktoria Palm, Subasini Thangamani, Bettina Katalin Budai, et al.
Breast (Edinburgh, Scotland)|September 10, 2023
Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)Thomas Decker, Kerstin Lüdtke-Heckenkamp, Luidmila Melnichuk, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 5, 2026
Is the gut a reservoir of non-tuberculous mycobacteria in people with cystic fibrosis?Jennifer Hudson, Nicole Taylor, Michael J Coffey, et al.
Molecular Phylogenetics and Evolution|December 17, 2017
Diversity and biogeography of frogs in the genus Amnirana (Anura: Ranidae) across sub-Saharan AfricaGregory F M Jongsma, Michael F Barej, Christopher D Barratt, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 4, 2023
Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulatorsCarla Colombo, Grant A Ramm, Anders Lindblad, et al.
International Journal of Cancer|December 21, 2024
Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registryMarc Thill, Mark-Oliver Zahn, Anja Welt, et al.
Pageof 23

Showing results (181-190 of 230) with videos related to

Sort By:
Pageof 23
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 6, 2021
Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patientsMichael Metz, Dieter Semsek, Gunther Rogmans, et al.
Circulation Research|May 20, 2006
Formation of the venous pole of the heart from an Nkx2-5-negative precursor population requires Tbx18Vincent M Christoffels, Mathilda T M Mommersteeg, Mark-Oliver Trowe, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 5, 2021
Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort studyCarla Colombo, Gianfranco Alicandro, Mark Oliver, et al.
Clinical Genitourinary Cancer|August 2, 2024
Final Analysis of a Noninterventional Study on Cabozantinib in Patients With Advanced Renal Cell Carcinoma After Prior Checkpoint Inhibitor Therapy of the German Interdisciplinary Working Group on Renal Tumors (IAG-N)Grünwald Viktor, Bögemann Martin, Rafiyan Mohammad-Reza, et al.
Scientific Reports|July 2, 2025
AI-based CT assessment of 3117 vertebrae reveals significant sex-specific vertebral height differencesViktoria Palm, Subasini Thangamani, Bettina Katalin Budai, et al.
Breast (Edinburgh, Scotland)|September 10, 2023
Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)Thomas Decker, Kerstin Lüdtke-Heckenkamp, Luidmila Melnichuk, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 5, 2026
Is the gut a reservoir of non-tuberculous mycobacteria in people with cystic fibrosis?Jennifer Hudson, Nicole Taylor, Michael J Coffey, et al.
Molecular Phylogenetics and Evolution|December 17, 2017
Diversity and biogeography of frogs in the genus Amnirana (Anura: Ranidae) across sub-Saharan AfricaGregory F M Jongsma, Michael F Barej, Christopher D Barratt, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 4, 2023
Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulatorsCarla Colombo, Grant A Ramm, Anders Lindblad, et al.
International Journal of Cancer|December 21, 2024
Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registryMarc Thill, Mark-Oliver Zahn, Anja Welt, et al.
Pageof 23